VERAXA Biotech and Secarna Report Positive Early Results from Antibody Oligonucleotide Collaboration

VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining the companies' technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of this approach to selectively deliver therapeutic oligonucleotides to disease-specific cells.

The companies stated that they are discussing next steps in the collaboration, which VERAXA noted demonstrates the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors. This development is significant as it expands the utility of VERAXA's platform into new therapeutic areas, potentially addressing unmet medical needs in autoimmune and chronic immune conditions.

According to the press release, the collaboration combines VERAXA's expertise in antibody engineering and conjugation with Secarna's proprietary antisense oligonucleotide platform. The positive early results validate the concept that conjugating oligonucleotides to antibodies can enhance their potency and specificity, potentially leading to more effective treatments with fewer side effects compared to unconjugated oligonucleotides.

For investors and industry observers, this news is important because it underscores the versatility of VERAXA's technology and its potential to generate value beyond its current pipeline focused on oncology. The ability to apply the same conjugation platform to autoimmune diseases could open up new market opportunities and diversify the company's revenue streams. Additionally, successful development of AOCs could represent a significant advancement in the field of targeted therapeutics, offering a new modality for treating diseases that are currently managed with systemic immunosuppressants or biologics.

The collaboration between VERAXA and Secarna began earlier, and these initial results are a key milestone. The companies have not disclosed specific financial terms or timelines for future development, but they indicated that discussions are underway to determine the next phase of the collaboration. This could involve advancing the lead AOC candidate into preclinical and clinical studies, which would be a critical step toward bringing this novel therapy to patients.

VERAXA Biotech is known for its innovative antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). Secarna is a privately held biopharmaceutical company specializing in antisense oligonucleotide therapies. The combination of these two technologies has the potential to create a new class of drugs that can precisely target disease-driving cells, improving efficacy and safety profiles.

For more information about VERAXA Biotech and its pipeline, visit the company's newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/IF9Cy.